Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia

Overview of attention for article published in Blood, January 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 9 X users

bluesky: 5 Bluesky users

Readers on

mendeley: 41 Mendeley

So far, Altmetric has seen 5 Bluesky posts from 5 Bluesky users, with an upper bound of 1,851 followers.

12/n interestingly, the pathogenesis of AHA is strongly linked to C3 consumption too. So maybe there is a rare associations here. In fact, pegcetacoplan, recently approved for C3GN, can be used to treat AHA pubmed.ncbi.nlm.nih.gov/39486046/

RP @medicine.stitches.today: Pegcetacoplan treatment effectively increased hemoglobin levels and reduced hemolysis in patients with cold agglutinin disease and warm antibody autoimmune hemolytic anemia. by Roman E, Fattizzo B (...) Gertz MA et 6 al. in B…

Pegcetacoplan treatment effectively increased hemoglobin levels and reduced hemolysis in patients with cold agglutinin disease and warm antibody autoimmune hemolytic anemia. by Roman E, Fattizzo B (...) Gertz MA et 6 al. in Blood #MedSky 📖 read the art…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 1 additional Bluesky posts.